X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5251) 5251
Book Review (950) 950
Publication (491) 491
Book Chapter (68) 68
Conference Proceeding (35) 35
Newsletter (29) 29
Dissertation (16) 16
Newspaper Article (10) 10
Book / eBook (2) 2
Magazine Article (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3923) 3923
index medicus (3911) 3911
mantle cell lymphoma (2826) 2826
male (1883) 1883
oncology (1840) 1840
hematology (1676) 1676
female (1607) 1607
middle aged (1603) 1603
aged (1471) 1471
lymphoma, mantle-cell - pathology (1225) 1225
lymphomas (1111) 1111
lymphoma, mantle-cell - drug therapy (988) 988
adult (982) 982
rituximab (866) 866
lymphoma (776) 776
cancer (767) 767
chronic lymphocytic-leukemia (760) 760
lymphoma, mantle-cell - genetics (698) 698
non-hodgkins-lymphoma (682) 682
antineoplastic combined chemotherapy protocols - therapeutic use (676) 676
aged, 80 and over (661) 661
prognosis (617) 617
treatment outcome (607) 607
pathology (601) 601
lymphoma, mantle-cell - diagnosis (529) 529
chemotherapy (520) 520
follicular lymphoma (520) 520
abridged index medicus (500) 500
expression (494) 494
lymphoma, mantle-cell - metabolism (493) 493
antineoplastic agents - therapeutic use (492) 492
lymphoma, mantle-cell - therapy (488) 488
animals (432) 432
immunohistochemistry (424) 424
cell line, tumor (411) 411
transplantation (407) 407
cyclin d1 (405) 405
hemic and lymphatic diseases (404) 404
leukemia (394) 394
survival (384) 384
care and treatment (381) 381
mantle-cell lymphoma (379) 379
bortezomib (368) 368
apoptosis (362) 362
therapy (351) 351
diagnosis (345) 345
lymphoma, mantle-cell - mortality (345) 345
research (340) 340
analysis (291) 291
disease-free survival (287) 287
phase-ii (285) 285
immunophenotyping (283) 283
translocation, genetic (270) 270
diagnosis, differential (269) 269
antibodies, monoclonal, murine-derived (264) 264
recurrence (262) 262
flow cytometry (261) 261
survival analysis (255) 255
progression-free survival (254) 254
retrospective studies (254) 254
non-hodgkin's lymphomas (251) 251
gene (243) 243
medicine & public health (243) 243
mice (241) 241
immune system diseases (235) 235
article (233) 233
antineoplastic agents - pharmacology (232) 232
multiple-myeloma (232) 232
b-cell lymphoma (228) 228
cell biology (227) 227
neoplasm staging (222) 222
survival rate (222) 222
hematology, oncology and palliative medicine (210) 210
in situ hybridization, fluorescence (210) 210
lymphoma, mantle-cell - immunology (210) 210
gene expression (209) 209
mantle cell (209) 209
combined modality therapy (208) 208
genetic aspects (208) 208
chronic lymphocytic leukemia (207) 207
lymphoma, non-hodgkin - pathology (205) 205
gene expression regulation, neoplastic (203) 203
antibodies, monoclonal - therapeutic use (202) 202
remission induction (202) 202
tumors (202) 202
lymphoma, mantle-cell - complications (198) 198
antineoplastic combined chemotherapy protocols - administration & dosage (192) 192
lymphoma, non-hodgkin - drug therapy (190) 190
cyclophosphamide - administration & dosage (189) 189
transplantation, autologous (189) 189
apoptosis - drug effects (188) 188
non-hodgkins-lymphomas (188) 188
non-hodgkin lymphoma (187) 187
follow-up studies (186) 186
cyclin d1 - genetics (185) 185
classification (184) 184
mantle (184) 184
biopsy (183) 183
leukemia, lymphocytic, chronic, b-cell - pathology (181) 181
antineoplastic combined chemotherapy protocols - adverse effects (179) 179
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5001) 5001
Chinese (76) 76
French (62) 62
German (62) 62
Japanese (56) 56
Spanish (37) 37
Korean (26) 26
Russian (12) 12
Czech (11) 11
Polish (11) 11
Portuguese (8) 8
Hungarian (7) 7
Turkish (3) 3
Danish (2) 2
Italian (2) 2
Serbian (2) 2
Slovak (2) 2
Croatian (1) 1
Dutch (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2015, Volume 372, Issue 10, pp. 944 - 953
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2016, Volume 175, Issue 3, pp. 410 - 418
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 13, pp. 1250 - 1260
The use of rituximab every 2 months for 3 years after immunochemotherapy and autologous stem-cell transplantation prolonged progression-free and overall... 
TRIAL | SURVIVAL | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | IMMUNOCHEMOTHERAPY | NORDIC MCL2 | FOLLOW-UP | HIGH-DOSE CYTARABINE | PHASE-3 | INTERGROUP | MCL YOUNGER | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Dexamethasone - administration & dosage | Humans | Middle Aged | Immunologic Factors - administration & dosage | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Lymphoma, Mantle-Cell - drug therapy | Male | Transplantation, Autologous | Combined Modality Therapy | Cytarabine - administration & dosage | Cisplatin - administration & dosage | Lymphoma, Mantle-Cell - mortality | Rituximab - administration & dosage | Lymphoma, Mantle-Cell - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Adult | Female | Aged | Maintenance Chemotherapy | Care and treatment | Usage | Patient outcomes | Mantle cell lymphoma | Stem cells | Outcome and process assessment (Health Care) | Reports | Transplantation | Observations | Medical research | Autografts | Dexamethasone | Cell survival | Hypersensitivity | Stem cell transplantation | Rituximab | Lymphoma | Cancer therapies | Survival | Studies | Chemotherapy | Cytarabine | Platinum | Lymphomas | Index Medicus | Abridged Index Medicus | Life Sciences | Hematology | Human health and pathology
Journal Article
British Journal of Haematology, ISSN 0007-1048, 07/2014, Volume 166, Issue 1, pp. 98 - 108
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 19, pp. 1835 - 1844
Journal Article
The Lancet, ISSN 0140-6736, 02/2018, Volume 391, Issue 10121, pp. 633 - 634
Mantle cell lymphoma is a rare, distinct subtype of non-Hodgkin lymphoma, with a disparate clinical course that varies from indolent at times to frequently... 
MEDICINE, GENERAL & INTERNAL | PHASE-II | BORTEZOMIB | Pyrazines | Benzamides | Lymphoma, Mantle-Cell | Humans | Lymphomas | Inhibitor drugs | Patients | Lymphoma | Drug dosages | Mantle cell lymphoma | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 6, pp. 507 - 516
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2018, Volume 378, Issue 13, pp. 1211 - 1223
Among patients with MCL, many of whom were at high risk, ibrutinib plus venetoclax led to a complete response in 62% at week 16. Among patients with a... 
MEDICINE, GENERAL & INTERNAL | BRUTONS TYROSINE KINASE | WORKING GROUP | PHASE | PROGRESSION-FREE SURVIVAL | RESPONSE ASSESSMENT | CHRONIC LYMPHOCYTIC-LEUKEMIA | NON-HODGKIN-LYMPHOMA | OPEN-LABEL | INHIBITOR | MINIMAL RESIDUAL DISEASE | Lymph Nodes - pathology | Prognosis | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Lymphoma, Mantle-Cell - mortality | Neoplasm, Residual | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Aged, 80 and over | Female | Historically Controlled Study | Lymphoma, Mantle-Cell - genetics | Pyrazoles - adverse effects | Administration, Oral | Pyrimidines - administration & dosage | Lymphoma, Mantle-Cell - drug therapy | Survival Rate | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Bone Marrow Examination | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Agammaglobulinaemia Tyrosine Kinase | Intention to Treat Analysis | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Mutation | Sulfonamides - administration & dosage | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Safety and security measures | Drug therapy | Mantle cell lymphoma | Flow cytometry | p53 Protein | Leukemia | Clinical trials | Cancer therapies | Computed tomography | Vomiting | Bone marrow | Medical research | Risk groups | Hematology | Minimal residual disease | Diarrhea | Fatigue | Nausea | Patients | Lymphoma | Bruton's tyrosine kinase | Polymerase chain reaction | Chemotherapy | Lysis | Response rates | Lymphomas | Positron emission tomography | Index Medicus | Abridged Index Medicus
Journal Article